[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640080":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":62,"collaborators":64,"id":71,"slug":20,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":20,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":50,"whyStopped":20,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Oregon Health and Science University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CMI","EXPERIMENTAL","Switching from mavacamten on day 1 to aficamten starting at week 2.",[13],"Drug: Aficamten",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Aficamten","Patients will be switched from mavacamten to aficamten. Mavacamten will be stopped at enrollment, and aficamten started 2 weeks later.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ahmad Masri","CONTACT","503-494-7551","masria@ohsu.edu",[28,48],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"St. Luke's Hospital - Mid America Heart Institute","NOT_YET_RECRUITING","Kansas City","Missouri","64111","United States",{"type":36,"coordinates":37},"Point",[38,39],-94.57857,39.09973,{"lat":39,"lon":38},[42,46],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Michael Nassif, MD","816-932-3458","mnassif@saint-lukes.org",{"name":43,"role":47,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":34,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Oregon Health & Science University","RECRUITING","Portland","Oregon","97239",{"type":36,"coordinates":55},[56,57],-122.67621,45.52345,{"lat":57,"lon":56},[60],{"name":61,"role":24,"phone":25,"phoneExt":20,"email":26},"Ahmad Masri, MD",{"type":47,"investigatorFullName":23,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Associate Professor",[65,68],{"name":66,"class":67},"Saint Lukes Hospital Mid America Heart Institute","UNKNOWN",{"name":69,"class":70},"Cytokinetics","INDUSTRY","100640080",false,"NCT07600177","Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy","CMI-SWITCH","Inclusion Criteria:\n\n* Documented history of oHCM with documented resting and\u002For Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially.\n* Echo-derived LVEF ≥55% on mavacamten at the time of enrollment.\n* Patient willing to consent for the study and undergo the study procedures.\n\nExclusion Criteria:\n\n* Severe aortic stenosis or sub-aortic obstruction\n* Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis).\n* History of LVEF \\\u003C30%.\n* Paroxysmal atrial fibrillation (AF) with documented episode within 3 months.\n* Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation.\n* Documented history of current obstructive coronary artery disease (\\> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.","ALL","18 Years","90 Years",{"count":81,"type":82},40,"ESTIMATED","INTERVENTIONAL",[85],"PHASE4","This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).",[88],"Hypertrophic Cardiomyopathy (HCM)",[90,91,92,9],"aficamten","mavacamten","cardiac myosin inhibitor","2026-05-14",{"date":95,"type":96},"2026-05-20","ACTUAL",{"date":98,"type":96},"2026-05-05",{"date":100,"type":82},"2027-03-15",{"name":5,"class":6},2]